| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 58 | 2024 | 563 | 8.580 |
Why?
|
| Staphylococcus aureus | 54 | 2024 | 479 | 7.850 |
Why?
|
| Streptococcus pneumoniae | 29 | 2026 | 388 | 7.850 |
Why?
|
| Pneumococcal Infections | 22 | 2026 | 279 | 7.220 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 27 | 2024 | 230 | 3.730 |
Why?
|
| Pneumococcal Vaccines | 16 | 2025 | 174 | 3.720 |
Why?
|
| Anti-Bacterial Agents | 60 | 2026 | 2563 | 3.230 |
Why?
|
| Microbial Sensitivity Tests | 44 | 2026 | 845 | 3.070 |
Why?
|
| Community-Acquired Infections | 29 | 2025 | 252 | 3.060 |
Why?
|
| Osteomyelitis | 13 | 2024 | 209 | 2.710 |
Why?
|
| Hospitals, Pediatric | 15 | 2025 | 797 | 2.500 |
Why?
|
| Bacteremia | 17 | 2025 | 428 | 2.030 |
Why?
|
| Pneumonia, Pneumococcal | 5 | 2026 | 88 | 2.000 |
Why?
|
| Serogroup | 12 | 2025 | 63 | 1.890 |
Why?
|
| Cross Infection | 13 | 2021 | 332 | 1.710 |
Why?
|
| Child | 79 | 2026 | 26075 | 1.480 |
Why?
|
| Child, Preschool | 64 | 2026 | 14937 | 1.460 |
Why?
|
| Infant | 55 | 2026 | 13229 | 1.300 |
Why?
|
| Helicobacter pylori | 12 | 2021 | 1367 | 1.290 |
Why?
|
| Methicillin Resistance | 18 | 2015 | 116 | 1.260 |
Why?
|
| Arthritis, Infectious | 4 | 2018 | 64 | 1.240 |
Why?
|
| Anti-Infective Agents, Local | 4 | 2019 | 70 | 1.190 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2021 | 395 | 1.090 |
Why?
|
| Meningitis, Bacterial | 3 | 2021 | 98 | 1.070 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 186 | 1.050 |
Why?
|
| Meningitis, Pneumococcal | 2 | 2018 | 42 | 1.010 |
Why?
|
| Helicobacter Infections | 8 | 2021 | 1307 | 1.010 |
Why?
|
| Adhesins, Bacterial | 5 | 2020 | 74 | 0.990 |
Why?
|
| Multilocus Sequence Typing | 10 | 2024 | 62 | 0.980 |
Why?
|
| Serotyping | 13 | 2026 | 172 | 0.980 |
Why?
|
| Haemophilus Infections | 3 | 2025 | 97 | 0.960 |
Why?
|
| Haemophilus influenzae | 3 | 2025 | 134 | 0.960 |
Why?
|
| Soft Tissue Infections | 7 | 2024 | 89 | 0.960 |
Why?
|
| Adolescent | 47 | 2026 | 20708 | 0.940 |
Why?
|
| Streptococcal Infections | 2 | 2021 | 254 | 0.930 |
Why?
|
| Leukocidins | 12 | 2018 | 37 | 0.920 |
Why?
|
| Exotoxins | 12 | 2018 | 44 | 0.920 |
Why?
|
| Humans | 130 | 2026 | 130255 | 0.910 |
Why?
|
| Hospitalization | 7 | 2026 | 1926 | 0.900 |
Why?
|
| Male | 76 | 2026 | 64350 | 0.900 |
Why?
|
| Texas | 29 | 2025 | 3639 | 0.860 |
Why?
|
| Female | 74 | 2026 | 70265 | 0.830 |
Why?
|
| Bacterial Toxins | 12 | 2018 | 170 | 0.810 |
Why?
|
| Organ Transplantation | 2 | 2016 | 170 | 0.790 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2026 | 1270 | 0.790 |
Why?
|
| Vaccines, Conjugate | 5 | 2023 | 84 | 0.770 |
Why?
|
| Sinusitis | 3 | 2014 | 118 | 0.760 |
Why?
|
| Respiratory Tract Infections | 3 | 2025 | 296 | 0.740 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 40 | 0.730 |
Why?
|
| Incidence | 13 | 2026 | 3315 | 0.720 |
Why?
|
| Genes, Bacterial | 3 | 2020 | 214 | 0.720 |
Why?
|
| Infant, Newborn | 26 | 2025 | 8523 | 0.710 |
Why?
|
| Carrier State | 3 | 2011 | 81 | 0.700 |
Why?
|
| Tissue Fixation | 1 | 2021 | 38 | 0.690 |
Why?
|
| Ribotyping | 1 | 2021 | 49 | 0.670 |
Why?
|
| Gastric Mucosa | 2 | 2021 | 491 | 0.670 |
Why?
|
| Cefazolin | 1 | 2020 | 17 | 0.650 |
Why?
|
| United States | 18 | 2026 | 11838 | 0.630 |
Why?
|
| Staphylococcal Scalded Skin Syndrome | 1 | 2020 | 8 | 0.620 |
Why?
|
| Prospective Studies | 14 | 2026 | 6436 | 0.620 |
Why?
|
| Biofilms | 1 | 2020 | 92 | 0.600 |
Why?
|
| Genes, MDR | 1 | 2019 | 6 | 0.590 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 5 | 2001 | 18 | 0.580 |
Why?
|
| Pandemics | 3 | 2022 | 1160 | 0.570 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 72 | 0.560 |
Why?
|
| Virulence Factors | 6 | 2020 | 181 | 0.560 |
Why?
|
| Methicillin | 5 | 2023 | 42 | 0.560 |
Why?
|
| Orbital Cellulitis | 1 | 2018 | 15 | 0.560 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 146 | 0.540 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 86 | 0.540 |
Why?
|
| Cerebral Ventriculitis | 1 | 2017 | 16 | 0.530 |
Why?
|
| Retrospective Studies | 28 | 2026 | 17500 | 0.530 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 12 | 0.520 |
Why?
|
| Abscess | 2 | 2024 | 137 | 0.510 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 11 | 2019 | 91 | 0.510 |
Why?
|
| Sepsis | 4 | 2021 | 494 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 887 | 0.500 |
Why?
|
| Molecular Epidemiology | 8 | 2020 | 141 | 0.480 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 154 | 0.470 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 76 | 0.460 |
Why?
|
| Membrane Transport Proteins | 3 | 2019 | 177 | 0.450 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 391 | 0.440 |
Why?
|
| Bacterial Adhesion | 2 | 2010 | 104 | 0.440 |
Why?
|
| Streptococcus | 1 | 2015 | 64 | 0.430 |
Why?
|
| Prostate | 1 | 2017 | 400 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 14 | 2011 | 1455 | 0.420 |
Why?
|
| Crohn Disease | 7 | 2001 | 287 | 0.420 |
Why?
|
| Bacterial Typing Techniques | 11 | 2021 | 97 | 0.420 |
Why?
|
| Antigens, Bacterial | 5 | 2025 | 318 | 0.410 |
Why?
|
| Genotype | 10 | 2020 | 2590 | 0.400 |
Why?
|
| Penicillins | 4 | 2024 | 152 | 0.390 |
Why?
|
| Down Syndrome | 1 | 2015 | 234 | 0.370 |
Why?
|
| In Situ Hybridization | 4 | 2001 | 437 | 0.360 |
Why?
|
| Amoxicillin | 3 | 2023 | 116 | 0.360 |
Why?
|
| Population Surveillance | 3 | 2018 | 393 | 0.360 |
Why?
|
| Chlorhexidine | 3 | 2017 | 48 | 0.350 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2021 | 57 | 0.340 |
Why?
|
| Vancomycin | 5 | 2018 | 221 | 0.340 |
Why?
|
| Paratuberculosis | 3 | 2000 | 17 | 0.330 |
Why?
|
| Diabetes Complications | 1 | 2012 | 197 | 0.320 |
Why?
|
| Nasal Cavity | 1 | 2011 | 56 | 0.320 |
Why?
|
| Empyema | 2 | 2025 | 23 | 0.300 |
Why?
|
| Bacterial Proteins | 7 | 2019 | 938 | 0.290 |
Why?
|
| Staphylococcal Skin Infections | 5 | 2024 | 37 | 0.280 |
Why?
|
| DNA, Bacterial | 12 | 2021 | 480 | 0.280 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2008 | 31 | 0.270 |
Why?
|
| Azithromycin | 3 | 1997 | 48 | 0.270 |
Why?
|
| Prevalence | 6 | 2018 | 2686 | 0.260 |
Why?
|
| Sensitivity and Specificity | 7 | 2023 | 2088 | 0.260 |
Why?
|
| Chlamydophila pneumoniae | 2 | 1997 | 10 | 0.260 |
Why?
|
| Young Adult | 12 | 2021 | 9991 | 0.250 |
Why?
|
| Multiplex Polymerase Chain Reaction | 2 | 2023 | 35 | 0.250 |
Why?
|
| Child, Hospitalized | 1 | 2026 | 77 | 0.230 |
Why?
|
| Empyema, Pleural | 1 | 2025 | 26 | 0.230 |
Why?
|
| Disease Outbreaks | 6 | 2022 | 314 | 0.220 |
Why?
|
| Mupirocin | 3 | 2015 | 20 | 0.220 |
Why?
|
| Streptococcus pyogenes | 2 | 2023 | 83 | 0.210 |
Why?
|
| Transplantation Conditioning | 1 | 2026 | 326 | 0.210 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 564 | 0.210 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2005 | 70 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2019 | 1224 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12829 | 0.200 |
Why?
|
| Penicillin G | 1 | 2023 | 18 | 0.190 |
Why?
|
| Clarithromycin | 3 | 1997 | 133 | 0.190 |
Why?
|
| Body Fluids | 1 | 2023 | 45 | 0.190 |
Why?
|
| Monte Carlo Method | 1 | 2023 | 97 | 0.190 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1622 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2019 | 373 | 0.180 |
Why?
|
| Adult | 16 | 2021 | 31094 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1486 | 0.180 |
Why?
|
| Enterobacter | 1 | 2021 | 13 | 0.180 |
Why?
|
| Mastoiditis | 2 | 2015 | 33 | 0.180 |
Why?
|
| Cronobacter sakazakii | 1 | 2021 | 4 | 0.180 |
Why?
|
| Fixatives | 1 | 2021 | 15 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2023 | 525 | 0.170 |
Why?
|
| Formaldehyde | 1 | 2021 | 50 | 0.170 |
Why?
|
| Spheroplasts | 1 | 2000 | 2 | 0.170 |
Why?
|
| Virus Diseases | 2 | 2022 | 284 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 7 | 2020 | 1694 | 0.170 |
Why?
|
| Cattle Diseases | 1 | 2000 | 20 | 0.160 |
Why?
|
| Cell Wall | 1 | 2000 | 44 | 0.160 |
Why?
|
| Infant Formula | 1 | 2021 | 105 | 0.160 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 309 | 0.160 |
Why?
|
| Aged | 12 | 2021 | 20840 | 0.160 |
Why?
|
| Helicobacter | 2 | 1998 | 18 | 0.160 |
Why?
|
| Rifabutin | 1 | 2020 | 4 | 0.160 |
Why?
|
| Immunization Schedule | 2 | 2019 | 111 | 0.160 |
Why?
|
| Biopsy | 2 | 2021 | 1241 | 0.160 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2020 | 65 | 0.160 |
Why?
|
| Cohort Studies | 4 | 2016 | 5047 | 0.160 |
Why?
|
| Water Supply | 2 | 1998 | 26 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 42 | 0.160 |
Why?
|
| Omeprazole | 1 | 2020 | 101 | 0.150 |
Why?
|
| Coinfection | 1 | 2021 | 186 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 446 | 0.150 |
Why?
|
| DNA Transposable Elements | 1 | 2020 | 180 | 0.150 |
Why?
|
| Public Health | 1 | 2021 | 272 | 0.150 |
Why?
|
| Antiporters | 1 | 2019 | 35 | 0.150 |
Why?
|
| Enterococcus | 1 | 2019 | 30 | 0.150 |
Why?
|
| Phylogeny | 3 | 2022 | 687 | 0.150 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 12 | 0.150 |
Why?
|
| Staphylococcus | 1 | 2019 | 68 | 0.150 |
Why?
|
| Medical Records | 1 | 2019 | 175 | 0.140 |
Why?
|
| Echocardiography | 1 | 2024 | 1128 | 0.140 |
Why?
|
| Bacteroides | 1 | 2019 | 36 | 0.140 |
Why?
|
| Skin | 2 | 2020 | 537 | 0.140 |
Why?
|
| Middle Aged | 11 | 2021 | 28336 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2019 | 277 | 0.140 |
Why?
|
| Bone Diseases, Infectious | 1 | 2018 | 8 | 0.140 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 108 | 0.140 |
Why?
|
| Comorbidity | 4 | 2017 | 1582 | 0.140 |
Why?
|
| Ranitidine | 1 | 1997 | 31 | 0.140 |
Why?
|
| Recurrence | 3 | 2016 | 1470 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1997 | 51 | 0.130 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 425 | 0.130 |
Why?
|
| Anti-Ulcer Agents | 1 | 1997 | 110 | 0.130 |
Why?
|
| Water Microbiology | 2 | 1998 | 27 | 0.130 |
Why?
|
| Colitis | 1 | 2019 | 164 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 282 | 0.130 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 3473 | 0.120 |
Why?
|
| Bacterial Capsules | 1 | 2016 | 42 | 0.120 |
Why?
|
| Ceftriaxone | 1 | 2016 | 69 | 0.120 |
Why?
|
| Patient Admission | 1 | 2018 | 185 | 0.120 |
Why?
|
| Endoscopy | 2 | 2014 | 267 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1374 | 0.120 |
Why?
|
| Doxycycline | 1 | 1997 | 111 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 333 | 0.120 |
Why?
|
| RNA, Bacterial | 2 | 2012 | 58 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 785 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 556 | 0.110 |
Why?
|
| Base Sequence | 3 | 2007 | 2737 | 0.110 |
Why?
|
| Retropharyngeal Abscess | 1 | 2015 | 7 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 351 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 363 | 0.110 |
Why?
|
| Mastoid | 1 | 2015 | 25 | 0.110 |
Why?
|
| Acute Disease | 4 | 2024 | 1147 | 0.110 |
Why?
|
| Ear, Middle | 1 | 2015 | 24 | 0.110 |
Why?
|
| Twins | 1 | 2015 | 71 | 0.110 |
Why?
|
| Otitis Media | 1 | 2015 | 88 | 0.110 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 8 | 0.100 |
Why?
|
| Length of Stay | 2 | 2018 | 1393 | 0.100 |
Why?
|
| Baths | 1 | 2013 | 14 | 0.100 |
Why?
|
| Disinfection | 1 | 2013 | 24 | 0.100 |
Why?
|
| Disinfectants | 1 | 2013 | 27 | 0.100 |
Why?
|
| Hygiene | 1 | 2013 | 24 | 0.100 |
Why?
|
| Lactobacillus | 1 | 2013 | 41 | 0.100 |
Why?
|
| Utah | 3 | 2020 | 83 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 51 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2013 | 6781 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 1166 | 0.100 |
Why?
|
| DNA Fingerprinting | 6 | 2010 | 106 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 760 | 0.100 |
Why?
|
| Age Factors | 1 | 2019 | 2826 | 0.090 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 416 | 0.090 |
Why?
|
| DNA | 1 | 1998 | 1400 | 0.090 |
Why?
|
| Glycemic Index | 1 | 2012 | 20 | 0.090 |
Why?
|
| Quinine | 1 | 2012 | 9 | 0.090 |
Why?
|
| Otitis | 1 | 2012 | 11 | 0.090 |
Why?
|
| Drug Resistance, Microbial | 4 | 2001 | 195 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 265 | 0.090 |
Why?
|
| Clindamycin | 3 | 2022 | 40 | 0.090 |
Why?
|
| Fractures, Spontaneous | 1 | 2012 | 19 | 0.090 |
Why?
|
| Age Distribution | 2 | 2010 | 422 | 0.090 |
Why?
|
| Genes, Essential | 1 | 2012 | 38 | 0.090 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 17 | 0.090 |
Why?
|
| Furunculosis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cattle | 3 | 2000 | 502 | 0.090 |
Why?
|
| Meat | 2 | 2000 | 44 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2013 | 324 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2014 | 1236 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2010 | 318 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 3031 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 3160 | 0.070 |
Why?
|
| Risk Factors | 5 | 2021 | 10938 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2011 | 289 | 0.070 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 136 | 0.070 |
Why?
|
| Cluster Analysis | 4 | 2011 | 412 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 4021 | 0.070 |
Why?
|
| Genomic Islands | 1 | 2007 | 29 | 0.070 |
Why?
|
| Hydrolases | 1 | 2007 | 61 | 0.070 |
Why?
|
| Virulence | 3 | 2005 | 271 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2007 | 198 | 0.060 |
Why?
|
| Neoplasms | 3 | 2013 | 2951 | 0.060 |
Why?
|
| Vagina | 1 | 2008 | 205 | 0.060 |
Why?
|
| Infection Control | 3 | 2015 | 162 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 446 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 261 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2006 | 31 | 0.060 |
Why?
|
| Health Personnel | 1 | 2011 | 550 | 0.060 |
Why?
|
| Animals | 7 | 2019 | 33775 | 0.060 |
Why?
|
| Myositis | 1 | 2006 | 104 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2005 | 76 | 0.060 |
Why?
|
| Clone Cells | 1 | 2005 | 152 | 0.050 |
Why?
|
| Penicillin Resistance | 1 | 2024 | 81 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 776 | 0.050 |
Why?
|
| Probability | 1 | 2005 | 306 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 163 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2004 | 53 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 501 | 0.050 |
Why?
|
| Pelvis | 1 | 2024 | 70 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 127 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2891 | 0.050 |
Why?
|
| Spondylitis | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vaccination | 2 | 2025 | 1051 | 0.050 |
Why?
|
| Pasteurella Infections | 1 | 2002 | 7 | 0.050 |
Why?
|
| Pasteurella multocida | 1 | 2002 | 7 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 48 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 74 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2002 | 25 | 0.050 |
Why?
|
| Candida albicans | 1 | 2002 | 88 | 0.050 |
Why?
|
| Cell Line | 2 | 1997 | 2559 | 0.050 |
Why?
|
| Northern Ireland | 1 | 2022 | 1 | 0.050 |
Why?
|
| Finland | 1 | 2022 | 46 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Norway | 1 | 2022 | 30 | 0.050 |
Why?
|
| Wound Infection | 1 | 2002 | 56 | 0.040 |
Why?
|
| Ships | 1 | 2022 | 8 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2024 | 213 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2022 | 135 | 0.040 |
Why?
|
| Nitroreductases | 1 | 2001 | 7 | 0.040 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2002 | 46 | 0.040 |
Why?
|
| Candidiasis | 1 | 2002 | 133 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2005 | 396 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2001 | 20 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2001 | 24 | 0.040 |
Why?
|
| Muramidase | 1 | 2000 | 37 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2022 | 198 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2000 | 51 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2022 | 137 | 0.040 |
Why?
|
| Phylogeography | 1 | 2020 | 11 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2012 | 3667 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 291 | 0.040 |
Why?
|
| Poland | 1 | 2020 | 56 | 0.040 |
Why?
|
| South Africa | 1 | 2020 | 98 | 0.040 |
Why?
|
| Photography | 1 | 2000 | 79 | 0.040 |
Why?
|
| Glycine | 1 | 2000 | 156 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2031 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2000 | 347 | 0.040 |
Why?
|
| DNA, Ribosomal | 2 | 2013 | 49 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2023 | 1611 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 48 | 0.040 |
Why?
|
| Prognosis | 2 | 2006 | 4854 | 0.040 |
Why?
|
| Waste Disposal, Fluid | 1 | 1998 | 7 | 0.040 |
Why?
|
| Fresh Water | 1 | 1998 | 15 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 264 | 0.040 |
Why?
|
| Lymecycline | 1 | 1997 | 1 | 0.030 |
Why?
|
| Taste Disorders | 1 | 1997 | 1 | 0.030 |
Why?
|
| Autoradiography | 1 | 1998 | 63 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 278 | 0.030 |
Why?
|
| Mouth Diseases | 1 | 1997 | 16 | 0.030 |
Why?
|
| Tongue | 1 | 1997 | 28 | 0.030 |
Why?
|
| Nausea | 1 | 1997 | 83 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2020 | 500 | 0.030 |
Why?
|
| Videotape Recording | 1 | 1997 | 54 | 0.030 |
Why?
|
| Hospitals | 2 | 2011 | 437 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1998 | 58 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1997 | 117 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 276 | 0.030 |
Why?
|
| Peptic Ulcer | 1 | 1998 | 149 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 81 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 644 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 209 | 0.030 |
Why?
|
| Half-Life | 1 | 1996 | 148 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1996 | 148 | 0.030 |
Why?
|
| Immunomagnetic Separation | 1 | 1996 | 10 | 0.030 |
Why?
|
| Intracellular Fluid | 1 | 1996 | 20 | 0.030 |
Why?
|
| Peru | 1 | 1996 | 54 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1996 | 79 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2000 | 901 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 290 | 0.030 |
Why?
|
| Diarrhea | 1 | 1997 | 315 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1996 | 296 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2011 | 344 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1481 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 720 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1121 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 1105 | 0.030 |
Why?
|
| Inflammation | 2 | 2019 | 1481 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 517 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 72 | 0.030 |
Why?
|
| Gastritis | 1 | 1998 | 372 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 1612 | 0.030 |
Why?
|
| Diterpenes | 1 | 2014 | 30 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 99 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1997 | 337 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2001 | 1590 | 0.030 |
Why?
|
| Eczema | 1 | 2013 | 35 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 236 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1870 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 2822 | 0.020 |
Why?
|
| Bedding and Linens | 1 | 2011 | 8 | 0.020 |
Why?
|
| Rats | 1 | 1998 | 3374 | 0.020 |
Why?
|
| Hospital Design and Construction | 1 | 2011 | 12 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 227 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 567 | 0.020 |
Why?
|
| Molecular Typing | 1 | 2011 | 32 | 0.020 |
Why?
|
| Bacillus | 1 | 2011 | 36 | 0.020 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2011 | 8 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 6197 | 0.020 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 407 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2000 | 254 | 0.020 |
Why?
|
| Synovial Fluid | 1 | 2009 | 15 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2009 | 58 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 126 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4711 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 320 | 0.020 |
Why?
|
| Temporal Bone | 1 | 2008 | 37 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4660 | 0.020 |
Why?
|
| Premature Birth | 1 | 2011 | 421 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 6085 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 25 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 2110 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 792 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3358 | 0.010 |
Why?
|
| Gentamicins | 1 | 2004 | 86 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 235 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 356 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 707 | 0.010 |
Why?
|
| Rifampin | 1 | 2004 | 122 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 191 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 236 | 0.010 |
Why?
|
| Sorbitol | 1 | 2002 | 8 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 2002 | 29 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 1088 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 2002 | 77 | 0.010 |
Why?
|
| Trehalose | 1 | 2002 | 21 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 1339 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2002 | 4 | 0.010 |
Why?
|
| Debridement | 1 | 2002 | 86 | 0.010 |
Why?
|
| Genes, rRNA | 1 | 2002 | 19 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5163 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 856 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2002 | 330 | 0.010 |
Why?
|
| Food Contamination | 1 | 2001 | 28 | 0.010 |
Why?
|
| Metronidazole | 1 | 2001 | 161 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2000 | 277 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 623 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2062 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 159 | 0.010 |
Why?
|
| Phenotype | 2 | 2002 | 4465 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2002 | 340 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 573 | 0.010 |
Why?
|
| Leprosy | 1 | 1999 | 16 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 291 | 0.010 |
Why?
|
| Sweden | 1 | 1998 | 37 | 0.010 |
Why?
|
| Magnetics | 1 | 1998 | 32 | 0.010 |
Why?
|
| Milk, Human | 1 | 2001 | 320 | 0.010 |
Why?
|
| Tetracycline | 1 | 1997 | 74 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2400 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 583 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1319 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 7413 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 877 | 0.010 |
Why?
|
| Tuberculosis | 1 | 1999 | 552 | 0.010 |
Why?
|